1 in 5 of these essential workers say they ‘definitely will not’ get the vaccine

<div id=”js-article__body” itemprop=”articleBody” data-sbid=”WP-MKTW-0000246127″>

While the general hesitancy about the U.S. coronavirus vaccine has diminished over time, new data suggests that people who have had to work outside the home during the pandemic in unsanitary settings show less inclination than others. groups to be vaccinated against COVID-19. Essential non-health workers (48%) are less likely than other non-health workers who work from home (69%) and people who are not currently working (67%) to say they have received at least one dose of the vaccine. coronavirus. or get vaccinated as soon as possible, according to a recently released KFF survey, conducted March 15-22.

21% of these essential workers, whose work environments include offices, factories and warehouses, delivery and transportation, and retail, say they will “definitely not” get the vaccine, and 11% say they will get it only if needed. In contrast, only 7% of those who work from home say they will definitely not get vaccinated, and 3% say they will only do so if necessary. Between the two groups, about one in five respondents said they wanted to “wait and see” first how vaccines work for other people. Vaccination intentions among essential non-health care workers diverged by political party, race, and educational lines: Republican and Republican-leaning workers (40%) were much more likely than their Democratic counterparts (5 %) to say that they would definitely not get vaccinated. as well as white workers (26%) versus black workers (7%) and Hispanics (11%). Meanwhile, non-college graduates doing essential work were much less likely than their college-educated counterparts to say they had received a dose of vaccine or planned to get vaccinated as soon as possible. These demographic differences do not fully explain the gap in vaccination intentions, the report noted. Even after controlling for those demographic and other factors, essential workers were still more likely than their non-essential counterparts to report that they would definitely not be vaccinated. “However, this analysis shows that among these factors, the strongest predictors of vaccine intentions are party identification and political ideology,” the authors added. Most essential workers who say they want to wait to get vaccinated, will receive the vaccine only if it is necessary, or will definitely not receive the vaccine have concerns about the possibility of experiencing serious side effects, and are required to get vaccinated even against his will. , or missing work due to side effects. Many essential unvaccinated workers also report that they lack sufficient information on where to get vaccinated (three out of 10) or are unsure of their eligibility within their state (nearly four out of 10), although the latter “may be mitigated in the future” according to states across the country. having extended the eligibility to all adults as of April 19. Essential non-health workers, particularly Republicans, are more likely than other groups (57%) to say that employers should not be able to require the COVID-19 vaccine for certain employees. The U.S. Equal Employment Opportunity Commission suggested in a guide published in December that employers can generally require their workers to get vaccinated against the coronavirus. So what could move the needle? About one in five essential workers say employer-provided incentives, such as on-site vaccinations and cash payments, would make them more likely to get vaccinated. The nationally representative survey of 1,862 adults, which outnumbered black and Hispanic individuals, included 477 essential non-health workers. The results for that subgroup included a sampling error of six percentage points. Many states have prioritized essential frontline workers in their vaccine launches. As of Monday, 42.5% of the US population had received at least one dose of vaccine and 28.9% had been fully vaccinated, according to the US Centers for Disease Control and Prevention. The vast majority of doses administered in the US have been the two-dose mRNA-based vaccines manufactured by Pfizer PFE, -0.12% with its German partner, BioNTech BNTX, + 0.32%, and Modern MRNA, + 2.83%. An advisory committee to the Centers for Disease Control and Prevention voted Friday to lift a federal “hiatus” in the use of the Johnson & Johnson JNJ vaccine at -0.90%, based on viral adenovirus vectors from one dose, without additional stipulations, following reports of ultra-rare cases but serious blood clots in combination with low platelet levels.